ICPT Share Price

Open 100.70 Change Price %
High 106.58 1 Day 3.54 3.55
Low 100.50 1 Week -1.21 -1.16
Close 103.24 1 Month 5.40 5.52
Volume 615076 1 Year -52.00 -33.50
52 Week High 177.93
52 Week Low 89.76
ICPT Important Levels
Resistance 2 108.88
Resistance 1 106.55
Pivot 103.44
Support 1 99.93
Support 2 97.60
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)

ICPT Technical Analysis 5
As on 5th Dec 2016 ICPT Share Price closed @ 103.24 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 137.59 & Strong Sell for SHORT-TERM with Stoploss of 131.78 we also expect STOCK to react on Following IMPORTANT LEVELS.
ICPT Target for December
1st Target up-side 116.85
2nd Target up-side 127.88
3rd Target up-side 138.91
1st Target down-side 85.39
2nd Target down-side 74.36
3rd Target down-side 63.33
ICPT Other Details
Segment EQ
Market Capital 330403136.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.interceptpharma.com
ICPT Address
ICPT
450 West 15th Street
New York, NY 10011
United States
Phone: 646-747-1000
Fax: 646-747-1001
ICPT Latest News
Interactive Technical Analysis Chart Intercept Pharmaceuticals, Inc. ( ICPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Intercept Pharmaceuticals, Inc.
ICPT Business Profile
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.